Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 8/20 | 0.70 |
| ▸ | KDR | P35968 | 8/20 | 0.70 |
| ▸ | JAK2 | O60674 | 2/20 | 0.70 |
| ▸ | RET | P07949 | 2/20 | 0.70 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.70 |
| ▸ | CDK1 | P06493 | 2/20 | 0.70 |
| ▸ | ROS1 | P08922 | 2/20 | 0.70 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.70 |
| ▸ | CDK2 | P24941 | 2/20 | 0.70 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.70 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.70 |
| ▸ | CLK2 | P49760 | 2/20 | 0.70 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.70 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.70 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.70 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.70 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.70 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.70 |
| ▸ | CDC7 | O00311 | 1/20 | 0.70 |
| ▸ | PLK4 | O00444 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24096480 | 0.89 | JAK2 (0.86) | SRCKDRJAK2RETDYRK3 | |
| SCHEMBL6107749 | 0.86 | AURKB (0.62) | SRCKDRJAK2RETDYRK3 | |
| SCHEMBL2960409 | 0.86 | AURKB (0.62) | SRCKDRJAK2RETDYRK3 | |
| SCHEMBL2960411 | 0.86 | AURKB (0.62) | SRCKDRJAK2RETDYRK3 | |
| SCHEMBL18539078 | 0.85 | SRC (0.76) | SRCKDRJAK2RETDYRK3 | |
| SCHEMBL6110209 | 0.84 | SRC (0.67) | SRCKDRJAK2RETDYRK3 | |
| SCHEMBL3817960 | 0.84 | SRC (0.67) | SRCKDRJAK2RETDYRK3 | |
| SCHEMBL17911543 | 0.84 | KDR (0.78) | SRCKDRJAK2RETDYRK3 | |
| SCHEMBL4826075 | 0.84 | KDR (0.78) | SRCKDRJAK2RETDYRK3 | |
| SCHEMBL4826083 | 0.84 | KDR (0.78) | SRCKDRJAK2RETDYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4116303-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | Loxo Oncology, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-3350184-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | LOXO ONCOLOGY INC (US) | 2022-10-19 | — | — | EP | disclosed |
| CN-114685516-A | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | 洛克索肿瘤学股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-108431007-B | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | 洛克索肿瘤学股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-10611766-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | LOXO ONCOLOGY INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-10399989-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | LOXO ONCOLOGY, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399990-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | LOXO ONCOLOGY, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180362533-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | REDX PHARMA PLC. (GB) | 2018-12-20 | — | — | US | disclosed |
| US-20180362537-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | REDX PHARMA PLC (GB) | 2018-12-20 | — | — | US | disclosed |
| US-20180298008-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | REDX PHARMA PLC (GB) | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611766-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | BTK, SYK, LCK | SRC 20/4885KDR 1370/4885JAK2 12/4885 |
| US-10399990-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | BTK, SYK, LCK | SRC 20/4885KDR 1370/4885JAK2 12/4885 |
| US-10399989-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | BTK, SYK, LCK | SRC 20/4885KDR 1370/4885JAK2 12/4885 |
| US-20180362537-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | BTK, SYK, LCK | SRC 20/4885KDR 1370/4885JAK2 12/4885 |
| US-20180298008-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | BTK, SYK, LCK | SRC 20/4885KDR 1370/4885JAK2 12/4885 |
| US-20180362533-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | BTK, SYK, LCK | SRC 20/4885KDR 1370/4885JAK2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.